Journal Article

Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial

Draisma, Annelies, Abdulla, Alan, Hunfeld, Nicole G. M, Karakus, Attila, Endeman, Henrik, Koch, Birgit C. P, Ewoldt, Tim M. J, Haringman, Jasper, van Vliet, Peter, Gommers, Diederik, Rietdijk, Wim J. R, Purmer, Ilse M, Rijpstra, Tom A, Muller, Anouk E, de Winter, Brenda C. M, Wils, Evert-Jan

2022

Overview

PurposeIndividualising drug dosing using model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin has been proposed as an alternative to standard dosing to optimise antibiotic efficacy in critically ill patients. However, randomised clinical trials (RCT) on clinical outcomes have been lacking.MethodsThis multicentre RCT, including patients admitted to the intensive care unit (ICU) who were treated with antibiotics, was conducted in eight hospitals in the Netherlands. Patients were randomised to MIPD with dose and interval adjustments based on monitoring serum drug levels (therapeutic drug monitoring) combined with pharmacometric modelling of beta-lactam antibiotics and ciprofloxacin. The primary outcome was ICU length of stay (LOS). Secondary outcomes were ICU mortality, hospital mortality, 28-day mortality, 6-month mortality, delta sequential organ failure assessment (SOFA) score, adverse events and target attainment.ResultsIn total, 388 (MIPD n = 189; standard dosing n = 199) patients were analysed (median age 64 [IQR 55–71]). We found no significant differences in ICU LOS between MIPD compared to standard dosing (10 MIPD vs 8 standard dosing; IRR = 1.16; 95% CI 0.96–1.41; p = 0.13). There was no significant difference in target attainment before intervention at day 1 (T1) (55.6% MIPD vs 60.9% standard dosing; p = 0.24) or at day 3 (T3) (59.5% vs 60.4%; p = 0.84). There were no significant differences in other secondary outcomes.ConclusionsWe could not show a beneficial effect of MIPD of beta-lactam antibiotics and ciprofloxacin on ICU LOS in critically ill patients. Our data highlight the need to identify other approaches to dose optimisation.

• Publisher: Springer Nature B.V
• Subject: Amides / Antibiotics / Ciprofloxacin / Clinical trials / Dosage / Drug dosages / Intensive care / Monitoring / Mortality / Optimization / Patients / Penicillin / Telemedicine / Therapeutic drug monitoring / β-Lactam antibiotics